Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following Surgery
NCT00500227 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 55
Last updated 2019-01-14
Summary
The objective of this study is to evaluate, in acromegalic patients with disease persistence after surgery who are treated with somatostatin analogues, the histopathological, clinical, morphological and biochemical factors which are predictive of hormonal control.
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Ipsen Medical Director · Ipsen
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2007-09-30
- Primary Completion
- 2012-07-31
- Completion
- 2012-07-31
Countries
- Spain
Study Locations
More Related Trials
-
Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic Subjects
NCT02807233 ·Status: COMPLETED
-
Somatostatin Analog Treatment of Acromegaly Before Pituitary Surgery : Comparison With Neurosurgery Alone
NCT01029275 ·Status: COMPLETED ·Phase: NA
-
Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues
NCT02354508 ·Status: COMPLETED ·Phase: PHASE3
-
Surgical Versus Medical Treatment of Acromegaly
NCT01000090 ·Status: COMPLETED
-
Patient and Physician Survey on Satisfaction With Somatostatin Analogue (SSA) Injections in Acromegaly in China
NCT05184231 ·Status: WITHDRAWN
-
Treatment Patterns and Treatment Outcomes for Acromegaly
NCT03043586 ·Status: COMPLETED
-
One Year Follow-up of Study 2-79-52030-207 (PRIMARYS) in Acromegalic Patients With Macroadenoma
NCT01471405 ·Status: COMPLETED
-
Impact of Somatostatin Analogs vs. Surgery on Glucose Metabolism in Acromegaly
NCT00703079 ·Status: COMPLETED
-
Description of Sign-and-symptom Associations at Acromegaly Diagnosis.
NCT02012127 ·Status: COMPLETED
-
Preoperative Octreotide Treatment of Acromegaly
NCT00521300 ·Status: COMPLETED ·Phase: PHASE4
-
Predictive Factors Study
NCT02020499 ·Status: TERMINATED
-
Acromegaly Resistant to Conventional Dose of First Generation Somatostatin Ligands
NCT06607666 ·Status: COMPLETED
-
Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients
NCT00210457 ·Status: COMPLETED ·Phase: PHASE3
-
A Prospective Study of Outcome After Therapy for Acromegaly
NCT01809808 ·Status: COMPLETED
-
Evaluation of Somatostatin Receptors and GH Receptor Expression on Bone of Acromegalic Patients (ACRO-BONE)
NCT05819554 ·Status: COMPLETED
-
Study to Predict Lanreotide-induced Disease Activity Normalization in Acromegaly
NCT04003519 ·Status: WITHDRAWN
-
Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease
NCT00434148 ·Status: COMPLETED ·Phase: PHASE3
-
Growth Hormone, IGF-1 and Medical Treatment in Acromegaly: Are There Effects on Gut Hormone Physiology and Postprandial Substrate Metabolism?
NCT02152124 ·Status: COMPLETED
-
Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
NCT00447499 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)
NCT00517491 ·Status: WITHDRAWN ·Phase: PHASE2
-
The Treatment and Natural History of Acromegaly
NCT00001981 ·Status: COMPLETED
-
An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly
NCT01995734 ·Status: APPROVED_FOR_MARKETING
-
Prediction of Tumor Shrinkage in Acromegaly
NCT00616408 ·Status: COMPLETED
-
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
NCT01137682 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly
NCT00499993 ·Status: COMPLETED ·Phase: PHASE3